Apicidin and Docetaxel Combination Treatment Drives CTCFL Expression and HMGB1 Release Acting as Potential Antitumor Immune Response Inducers in Metastatic Breast Cancer Cells

摘要: Abstract Currently approved combination regimens available for the treatment of metastatic tumors, such as breast cancer, have been shown to increase response rates, often at cost a substantial in toxicity. An ideal strategy may consist agents with different mechanisms action leading complementary antitumor activities and safety profiles. In present study, we investigated effects epigenetic modulator apicidin cytotoxic agent docetaxel tumor cell lines characterized by grades invasiveness. We report that combined docetaxel, low toxicity doses, stimulates cancer cells expression CTCF-like protein other antigens, thus potentially favoring an immune response. addition, co-treatment specifically apoptosis, increased Bax/Bcl-2 ratio caspase-8 activation. Importantly, following exposure these agents, were also found induce signals immunogenic apoptosis surface calreticulin release considerable amounts high-mobility group box 1 protein, promoting translation induced death into Altogether, our results indicate use profile, represent potential innovative able activate pathways cells, associated control growth possible induction immunity.